Amicogen’s ‘Enzyme · bio pharmaceuticals’ business has concentrated on the Green API business (eco-friendly raw material pharmaceutical production method) such as special enzymes and DX project and has led the development of eco-friendly technology in the global pharmaceutical market. In addition, in cooperation with global life science companies, Amicogen is promoting the endolysin business, a therapeutic agent for antibiotic-resistant mutant bacteria (super bacteria), so-called the next-generation antibiotics.

Amicogen’s ‘health care business’ develops and sells health functional food materials and finished products such as collagen (tree) peptide, pinitol/ DCI, N-acetylglucosamine, and health food enzyme by utilizing enzyme technologies (B2B, B2C).

The ‘bio process/ CDMO business’ has focused on the chromatography resin and medium business, which are essential for the biopharmaceutical production.